This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
CONMED Beats on Q3 Earnings, Misses on Sales, Lowers '24 Sales View
by Zacks Equity Research
CNMD's Q3 earnings beat estimates on the back of higher revenues and lower costs and expenses.
Conmed (CNMD) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Conmed (CNMD) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Conmed (CNMD) Surpasses Q3 Earnings Estimates
by Zacks Equity Research
Conmed (CNMD) delivered earnings and revenue surprises of 6.06% and 0.55%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Conmed (CNMD) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Conmed (CNMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Conmed (CNMD) is a Strong Growth Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Will Conmed (CNMD) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Conmed (CNMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why You Should Retain CONMED Stock in Your Portfolio
by Zacks Equity Research
CNMD is poised for growth with strong product offerings and recurring revenues but faces headwinds from regulatory challenges, supply-chain constraints and cybersecurity risks.
Here's Why Conmed (CNMD) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
New Strong Sell Stocks for September 26th
by Zacks Equity Research
AMTB, BZH and CNMD have been added to the Zacks Rank #24 (Strong Sell) List on September 26, 2024.
New Strong Sell Stocks for September 17th
by Zacks Equity Research
BAMXF, BZH and CNMD have been added to the Zacks Rank #5 (Strong Sell) List on September 17 2024.
New Strong Sell Stocks for September 11th
by Zacks Equity Research
B, CNMD and CHEOY have been added to the Zacks Rank #5 (Strong Sell) List on September 11, 2024.
Why Is Conmed (CNMD) Up 13.2% Since Last Earnings Report?
by Zacks Equity Research
Conmed (CNMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Do Options Traders Know Something About CONMED (CNMD) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to CONMED (CNMD) stock based on the movements in the options market lately.
New Strong Sell Stocks for August 19th
by Zacks Equity Research
ARRY, BSM and CNMD have been added to the Zacks Rank #5 (Strong Sell) List on August 19, 2024.
New Strong Sell Stocks for August 15th
by Zacks Equity Research
ARCO, CNMD and CVS have been added to the Zacks Rank #5 (Strong Sell) List on August 15, 2024.
New Strong Sell Stocks for August 5th
by Zacks Equity Research
AMX, CNH and CNMD have been added to the Zacks Rank #5 (Strong Sell) List on August 5, 2024.
CONMED (CNMD) Q2 Earnings Beat, Sales Rise Y/Y, '24 View Cut
by Zacks Equity Research
CONMED (CNMD) beats second-quarter earnings estimates on the back of higher revenues and lower costs and expenses. However, the result reflects the continued impact of supply chain issues.
Here's What Key Metrics Tell Us About Conmed (CNMD) Q2 Earnings
by Zacks Equity Research
Although the revenue and EPS for Conmed (CNMD) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Conmed (CNMD) Q2 Earnings Beat Estimates
by Zacks Equity Research
Conmed (CNMD) delivered earnings and revenue surprises of 6.52% and 0.74%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Conmed (CNMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Conmed (CNMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.
Staar Surgical (STAA) Soars 7.5%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Staar Surgical (STAA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Henry Schein (HSIC) Down 4.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.